Bit.bio cuts 25% of staff as it shifts from therapy development to lab research
FierceBiotech - 19-Mar-2025Company aims to grow its product line and biotech partnerships
Join the club for FREE to access the whole archive and other member benefits.
Staff writer for Fierce Biotech
Gabrielle Masson is a staff writer for Fierce Biotech. Prior to Fierce, she worked at Becker's Hospital Review for almost three years, where she reported on public health and the pandemic. Gabrielle graduated from the University of Wisconsin-Madison in 2019 after studying creative writing and criminal justice in both Wisconsin and Cape Town, South Africa. A current resident of Chicago, Gabrielle spends her free time scouting out the best restaurants, curating playlists and writing poetry.
Visit website: https://www.fiercebiotech.com/person/gabrielle-masson-0
See also
Web resource providing the latest biotech news, articles, and resources related to biotech company news
Details last updated 16-Aug-2022
Company aims to grow its product line and biotech partnerships
Regeneron’s DB-OTO offers new hope for genetic hearing loss
Early trial results show promise for insulin production without immune suppression
Drug improved chronic cough symptoms, contributing to a better quality of life\
Biotech firm Bioage plans public debut as it advances promising obesity treatments
The company remains focused on its independent cancer drug development
Phase 2 trial results show significant vision improvement, plans for FDA approval
Let's hope their research is either successful for the company or its successors